Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BGB-B167 |
Trade Name | |
Synonyms | BGB B167|BGBB167 |
Drug Descriptions |
BGB-B167 is a bispecific antibody that targets CEACAM5 (CEA) and TNFRSF9 (4-1BB), which potentially induces antitumor activity (Cancer Res (2024) 84 (6_Supplement): 2371). |
DrugClasses | CEACAM5 Antibody 8 TNFRSF9 Antibody 32 |
CAS Registry Number | NA |
NCIT ID | C192095 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BGB-B167 | BGB-B167 | 0 | 0 |
BGB-B167 + Tislelizumab | BGB-B167 Tislelizumab | 0 | 1 |